𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Residual exercise SPECT ischemia on treatment is a main determinant of outcome in patients with coronary artery disease treated medically at long-term with ß-blockers

✍ Scribed by Pierre Y Marie; Christelle Mercennier; Nicolas Danchin; Karim Djaballah; Alain Grentzinger; Faïez Zannad; Pierre Olivier; Wassila Djaballah; Gilles Karcher; Jean M Virion; Alain Bertrand


Publisher
Springer
Year
2003
Tongue
English
Weight
120 KB
Volume
10
Category
Article
ISSN
1071-3581

No coin nor oath required. For personal study only.

✦ Synopsis


Background:

Beta-blockers are potent anti-ischemic medications, able to improve prognosis in patients with coronary artery disease (cad). however, it is not known whether beta-blockers have the same beneficial prognostic effect when residual ischemia persists on treatment.

Methods and results:

The prognostic impact of exercise single photon emission computed tomography (spect) ischemia was analyzed in 442 patients with chronic cad, who were treated with beta-blockers and who were referred to exercise thallium 201 spect, while they were receiving their daily-life medications. ischemic and viable myocardium was documented on tl-201 spect in 190 patients (43%), of whom only 23% had angina and only 26% had positive exercise testing results. during a follow-up of 3.8 +/- 1.7 years, 36 patients died and survival curves were progressively divergent between patients with and those without ischemic and viable myocardium: at 5 years, the respective survival rates were 81% +/- 4% and 94% +/- 2% (p =.004). by multivariate analysis, the best independent predictors of death were large extent of necrosis (>25% of left ventricle on tl-201 spect, p <.001) and ischemic and viable myocardium (p =.001).

Conclusions:

In the cad patients treated on a long-term basis with beta-blockers, survival is strongly influenced by persistent exercise spect ischemia on treatment. therefore exercise spect on treatment could be a useful tool for selecting those who might benefit from additional anti-ischemic therapeutic interventions.